全文获取类型
收费全文 | 9347篇 |
免费 | 555篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 122篇 |
儿科学 | 164篇 |
妇产科学 | 221篇 |
基础医学 | 1382篇 |
口腔科学 | 111篇 |
临床医学 | 795篇 |
内科学 | 2031篇 |
皮肤病学 | 312篇 |
神经病学 | 689篇 |
特种医学 | 698篇 |
外科学 | 1418篇 |
综合类 | 60篇 |
一般理论 | 1篇 |
预防医学 | 419篇 |
眼科学 | 228篇 |
药学 | 480篇 |
中国医学 | 5篇 |
肿瘤学 | 803篇 |
出版年
2023年 | 47篇 |
2022年 | 73篇 |
2021年 | 148篇 |
2020年 | 123篇 |
2019年 | 166篇 |
2018年 | 215篇 |
2017年 | 168篇 |
2016年 | 176篇 |
2015年 | 223篇 |
2014年 | 241篇 |
2013年 | 384篇 |
2012年 | 554篇 |
2011年 | 592篇 |
2010年 | 337篇 |
2009年 | 330篇 |
2008年 | 562篇 |
2007年 | 535篇 |
2006年 | 530篇 |
2005年 | 493篇 |
2004年 | 497篇 |
2003年 | 485篇 |
2002年 | 379篇 |
2001年 | 171篇 |
2000年 | 180篇 |
1999年 | 190篇 |
1998年 | 115篇 |
1997年 | 97篇 |
1996年 | 87篇 |
1995年 | 75篇 |
1994年 | 74篇 |
1993年 | 55篇 |
1992年 | 115篇 |
1991年 | 99篇 |
1990年 | 116篇 |
1989年 | 106篇 |
1988年 | 101篇 |
1987年 | 100篇 |
1986年 | 86篇 |
1985年 | 71篇 |
1984年 | 77篇 |
1983年 | 72篇 |
1982年 | 51篇 |
1981年 | 45篇 |
1980年 | 41篇 |
1979年 | 47篇 |
1978年 | 43篇 |
1977年 | 41篇 |
1975年 | 39篇 |
1974年 | 45篇 |
1973年 | 45篇 |
排序方式: 共有9939条查询结果,搜索用时 31 毫秒
241.
Stephanie Dufek Tuula Holtta Michel Fischbach Gema Ariceta Augustina Jankauskiene Rimante Cerkauskiene Claus Peter Schmitt Betti Schaefer Christoph Aufricht Elizabeth Wright Constantinos J. Stefanidis Mesiha Ekim Sevcan Bakkaloglu Günter Klaus Aleksandra Zurowska Karel Vondrak Johan Vande Walle Alberto Edefonti Rukshana Shroff 《Pediatric nephrology (Berlin, Germany)》2015,30(11):2021-2027
242.
Extracorporeal CO2 removal as bridge to lung transplantation in life‐threatening hypercapnia
下载免费PDF全文
![点击此处可从《Transplant international》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Peter Schellongowski Katharina Riss Thomas Staudinger Roman Ullrich Claus G. Krenn Christian Sitzwohl Andja Bojic Philipp Wohlfarth Wolfgang R. Sperr Werner Rabitsch Clemens Aigner Shahrokh Taghavi Peter Jaksch Walter Klepetko György Lang 《Transplant international》2015,28(3):297-304
In patients awaiting lung transplantation (LTX), adequate gas exchange may not be sufficiently achieved by mechanical ventilation alone if acute respiratory decompensation arises. We report on 20 patients with life‐threatening hypercapnia who received extracorporeal CO2 removal (ECCO2‐R) by means of the interventional lung assist (ILA®, Novalung) as bridge to LTX. The most common underlying diagnoses were bronchiolitis obliterans syndrome, cystic fibrosis, and idiopathic pulmonary fibrosis, respectively. The type of ILA was pumpless arteriovenous or pump‐driven venovenous (ILA activve®, Novalung) in 10 patients each. ILA bridging was initiated in 15 invasively ventilated and five noninvasively ventilated patients, of whom one had to be intubated prior to LTX. Hypercapnia and acidosis were effectively corrected in all patients within the first 12 h of ILA therapy: PaCO2 declined from 109 (70–146) to 57 (45–64) mmHg, P < 0.0001; pH increased from 7.20 (7.06–7.28) to 7.39 (7.35–7.49), P < 0.0001. Four patients were switched to extracorporeal membrane oxygenation due to progressive hypoxia or circulatory failure. Nineteen patients (95%) were successfully transplanted. Hospital and 1‐year survival was 75 and 72%, respectively. Bridging to LTX with ECCO2‐R delivered by arteriovenous pumpless or venovenous pump‐driven ILA is feasible and associated with high transplantation and survival rates. 相似文献
243.
Characterization of onset mechanism and waveform analysis in patients with atrial fibrillation using a high-resolution noncontact mapping system 总被引:6,自引:0,他引:6
Weber S Ndrepepa G Schneider M Geissler B Schreieck J Karch M Schmieder S Deisenhofer I Zrenner B Schömig A Schmitt C 《Journal of cardiovascular electrophysiology》2003,14(2):176-181
INTRODUCTION: Information on the spatiotemporal organization of atrial activity at the onset of atrial fibrillation (AF) is limited. METHODS AND RESULTS: The study consisted of 26 consecutive patients (22 men and 4 women; mean age 56 +/- 9 years) with AF in whom the left atrium (LA) was mapped using a noncontact mapping system. At the onset of AF, the AF cycle lengths and wavefronts were analyzed at the site of origin of the triggering atrial premature complex (APC) and five predefined sites within the LA (superior, anterior, posterior, lateral, and septal walls). If repetitive activity was observed at the site of origin of APCs, triggered AF episodes were considered as focally driven. APCs that induced AF had shorter coupling intervals than APCs that did not induce AF (300 +/- 41 msec vs 392 +/- 64 msec, P < 0.001). Immediately after AF onset, repetitive firing was crucial for maintenance of arrhythmia in 52 (80%) of 65 AF episodes. In 13 AF onset episodes (20%), AF was maintained by other mechanisms. The number of LA wavefronts after AF onset was lower in focally driven AF episodes compared with episodes in which no focally driven activity was observed (1.9 +/- 0.6 v. 2.3 +/- 2.3 wavefronts, P < 0.05). After the onset of AF, the posterior wall of the LA showed the earliest disorganized activity (after 5.2 +/- 3.1 cycles). CONCLUSION: In the majority of AF episodes (80%), repetitive firing from the triggering foci may play an important role in maintaining AF immediately after arrhythmia onset. In 20% of the episodes, AF at early stages seems to be maintained by other mechanisms. The capability of APCs to induce AF depends on the coupling interval and the focus localization. The posterior wall of the LA shows the earliest disorganization of wavefronts at the onset of AF. 相似文献
244.
Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products
下载免费PDF全文
![点击此处可从《Annals of the rheumatic diseases》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Lehmann HJ Mouritzen U Christgau S Cloos PA Christiansen C 《Annals of the rheumatic diseases》2002,61(6):530-533
BACKGROUND: Animal studies of arthritis have suggested that bisphosphonates may have chondroprotective abilities. OBJECTIVE: To evaluate the effect of bisphosphonate treatment on cartilage degradation. METHODS: Type II collagen is almost exclusively localised in cartilage, where it is the major structural component of the tissue. Hence fragments derived from this protein should represent a specific index for cartilage degradation. The urinary concentration of collagen type II C-telopeptide degradation products (CTX-II) was measured by a new immunoassay (enzyme linked immunosorbent assay (ELISA)). The serum concentration of collagen type I C-telopeptide degradation products (CTX-I), a marker of bone degradation, was also measured by ELISA. PARTICIPANTS: Two groups were studied. The alendronate group included 63 healthy postmenopausal women aged 45-54 randomly allocated to receive three years' treatment with 1 mg, 5 mg, 10 mg, or 20 mg alendronate daily or placebo. In the third year the women receiving 20 mg were switched to placebo. The ibandronate group included 119 women at least 10 years after the menopause aged <75 randomly allocated to receive 12 months' treatment with 0.25 mg, 0.5 mg, 1.0 mg, 2.5 mg, or 5 mg ibandronate daily or placebo followed by 12 months without treatment. RESULTS: 20 mg of alendronate and 2.5 and 5 mg of ibandronate treatment produced significant decreases in urinary CTX-II to about 50% of baseline. The level reached after three months of treatment remained practically constant during the following 12-36 treatment months. When treatment was withdrawn CTX-II values returned towards baseline. Serum CTX-I also decreased rapidly within three months, but to a level of about 30% of baseline. CONCLUSIONS: The urinary excretion of CTX-II, a new marker of cartilage degradation, decreases significantly in response to bisphosphonate. This suggests that bisphosphonates may have chondroprotective effects in humans. By measurement of CTX-II it should be possible to monitor the effects of drugs that potentially inhibit cartilage destruction. 相似文献
245.
The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism 总被引:3,自引:0,他引:3
J S Johansen B J Riis C Hassager M Moen J Jacobson C Christiansen 《The Journal of clinical endocrinology and metabolism》1988,67(4):701-706
The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period. Bone mineral content in the forearm (measured by single photon absorptiometry) and in the spine (measured by dual photon absorptiometry) significantly decreased after 6 months of treatment with 400 micrograms nafarelin, but 6 months after termination of treatment all bone mineral measurements had returned to pretreatment levels. The bone mineral measurements in the 200 micrograms group did not change throughout the study. In both treatment groups the biochemical estimates of bone turnover increased significantly to postmenopausal levels. Withdrawal of treatment resulted in an abrupt decrease in the bone resorption parameters (fasting urinary hydroxyproline to creatinine and calcium to creatinine excretion ratios and serum phosphate), whereas there was a protracted fall in the bone formation parameters (plasma bone Gla protein and serum alkaline phosphatase) 6 months after termination of treatment. Our findings demonstrate that nafarelin in both doses increased biochemical indices of bone turnover, that 400 micrograms/day nafarelin resulted in a significant decrease in bone mineral content, and that these effects were reversible. 相似文献
246.
J Olsen P E Mortensen O B Schaffalitzky de Muckadell J J Holst J Christiansen 《Scandinavian journal of gastroenterology》1989,24(4):493-496
The inhibitory effect of intravenous infusion of secretin (0.05 CU kg-1h-1) and somatostatin (60 pmol kg-1h-1), given alone or in combination, on pentagastrin-stimulated (100 ng kg-1 h-1) acid secretion was studied in 10 healthy subjects. Secretin inhibited acid secretion by 54% (p less than 0.05), and somatostatin inhibited by 70% (p less than 0.05). The combined infusion of secretin and somatostatin decreased acid output by 64% (p less than 0.05). The differences between the three groups were not significant (p greater than 0.05). Median plasma concentrations of secretin and somatostatin were of the same magnitude as seen after duodenal acidification. The present study did not demonstrate any interaction between secretin and somatostatin in the inhibition of gastric acid secretion. 相似文献
247.
248.
Regulation of uncoupling protein-2 and -3 by growth hormone in skeletal muscle and adipose tissue in growth hormone-deficient adults 总被引:4,自引:0,他引:4
Pedersen SB Kristensen K Fisker S Jørgensen JO Christiansen JS Richelsen B 《The Journal of clinical endocrinology and metabolism》1999,84(11):4073-4078
The newly described uncoupling proteins, UCP2 and UCP3, may play a role in regulating energy expenditure (EE) in humans. GH deficiency (GHD) is associated with decreased lean body mass, increased adiposity, and reduced EE, which are reversed by GH treatment. In the present study we investigated whether GH treatment for 4 months influenced the expression of UCPs in skeletal muscle and adipose tissue in 22 GHD patients who were investigated before and after GH (n = 11) or placebo (n = 11) treatment. GH treatment increased the amount of lean body mass by 4.5% (P < 0.05) and decreased body fat mass by 12% (P < 0.05), whereas no changes in these parameters were observed after placebo treatment. The level of UCP3 messenger ribonucleic acid (mRNA) increased 3-fold (P < 0.005) in skeletal muscle and almost 2-fold (P < 0.05) in adipose tissue after GH treatment, with no changes observed after placebo treatment. Skeletal muscle UCP2 mRNA was slightly (25%), but significantly (P < 0.05), decreased, whereas the level of UCP2 mRNA in adipose tissue was unaffected after GH treatment. The T4 level was positively correlated with skeletal muscle UCP2 and UCP3 expression (r = 0.518; P < 0.05 and r = 0.463; P < 0.05, respectively). Furthermore, plasma free fatty acids were positively correlated with the expression of UCP2 (r = 0.573; P < 0.01) and UCP3 (r = 0.518; P < 0.05) in skeletal muscle. The marked increase in UCP3 expression after GH treatment indicates that the UCPs might play a role in the effects of GH on EE in GHD patients. Finally, the strong association between thyroid hormone and skeletal muscle UCP and the correlation between plasma free fatty acids and UCP expression in skeletal muscle indicate that these hormones/metabolites might influence UCP expression in humans as previously demonstrated in rodents. 相似文献
249.
Chen JW Frystyk J Lauritzen T Christiansen JS 《European journal of endocrinology / European Federation of Endocrine Societies》2005,153(6):907-913
OBJECTIVE: This study aimed to evaluate the impact of insulin antibodies on insulin aspart pharmaco-kinetics and pharmacodynamics after 12-week multiple daily injections of biphasic insulin aspart 30 (30% fast-acting and 70% protamine-crystallised insulin aspart, BIAsp30) in patients with type 1 diabetes. METHODS: Twenty-three patients (8 women, 15 men) aged 44.8 (20.6-62.5) years (median and range) with diabetes duration of 19.5 (1.6-44.6) years and haemoglobin (Hb)A(1C) of 9.2% (8.1-12.3%) participated in the study, which consisted of 12-week treatment with multiple injections of BIAsp30. At the end of the treatment period, all patients attended two 24-h profile days 1 week apart for pharmacokinetic and pharmacodynamic assessments. HbA(1C) and insulin antibodies were also determined. RESULTS: Patients were stratified into two groups depending on whether the level of insulin binding to insulin antibodies was below or above 75% (moderate vs high (%, median and range): 62 (15-74) vs 80 (75-89)). High levels of insulin antibodies resulted in about threefold increase in AUC((0 - 24 h)) (the area under the concentration-time curve during 24 h) for total insulin aspart (analysis of variance, P < 0.05). The differences in free insulin aspart pharmacokinetics, insulin pharmacodynamics and HbA(1C) were not statistically significant between patients with different levels of insulin antibodies. Total daily insulin dosage was significantly lower in patients with high than moderate levels of insulin antibodies. CONCLUSIONS: In type 1 diabetic patients, high levels of circulating insulin antibodies result in elevated total, but not free, insulin aspart profiles. Consistent with the finding of similar insulin pharmacodynamics, the long-term glycaemic control is not significantly different between patients with different levels of insulin antibodies. 相似文献